Welcome to our dedicated page for Sanara MedTech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara MedTech stock.
Sanara MedTech Inc. (SMTI) is a leading medical technology company that aims to revolutionize the wound care and skincare markets through innovative solutions. Founded in 1982 and headquartered in Fort Worth, Texas, Sanara MedTech focuses on developing and commercializing technologies that improve clinical outcomes for patients while simultaneously reducing healthcare costs.
The company operates through its subsidiary, Wound Care Innovations, LLC, and offers a range of collagen-based wound care products under the brand name CellerateRX. These products are marketed for treating various types of wounds, including pressure ulcers, diabetic ulcers, surgical wounds, and burns. Available in both gel and powder forms, CellerateRX is designed to serve healthcare providers such as physicians, clinics, and hospitals.
Sanara MedTech's portfolio extends beyond surgical wound care, encompassing a comprehensive suite of chronic wound care products. The company's notable offerings include HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel. These products enable Sanara MedTech to deliver extensive wound and skincare solutions across all care settings, from acute to post-acute environments.
With a strategic focus on transformative technologies, Sanara MedTech holds worldwide licenses for certain proprietary technologies and processes. This positions the company at the forefront of advancing wound care treatment protocols. Recent achievements highlight the company's commitment to innovation and quality, making it a key player in the medical technology landscape.
Sanara MedTech also prioritizes transparent communication with its investors and stakeholders. For the latest updates and developments, the company's investor relations team is readily accessible, ensuring stakeholders are well-informed about performance metrics, ongoing projects, and future prospects.
Overall, Sanara MedTech Inc. continues to set the standard in wound care and skincare solutions, contributing significantly to the healthcare sector by enhancing patient care and operational efficacy.
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound, and skincare markets, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place at The Lotte New York Palace from December 3-5, 2024. Ron Nixon, the Company's Chairman and CEO, will deliver a presentation to investors on December 4 at 11:50 a.m. Eastern Time. Presentation materials will be available on the company's investor relations website before the event, along with a live audio webcast and replay option.
Sanara MedTech (NASDAQ: SMTI) reported its Q3 2024 results, marking its twelfth consecutive record net revenue quarter. Net revenue increased 35% year-over-year to $21.7 million. The company reported a net loss of $2.9 million, compared to a $1.1 million loss in Q3 2023. The company expanded its distribution network to 300+ distributors and its products are now sold in over 1,200 facilities across 34 states. Sanara invested $5.0 million for a 6.64% stake in ChemoMouthpiece and secured exclusive U.S. distribution rights for their cryotherapy device.
Sanara MedTech (NASDAQ: SMTI), a medical technology company focused on surgical, chronic wound and skincare markets, has scheduled its Q3 2024 earnings release for November 12, 2024. The company will host a conference call on November 13, 2024, at 9:00 a.m. Eastern Time. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 373459) or webcast through the company's website. A replay will be available through November 27, 2024.
Sanara MedTech Inc. (NASDAQ: SMTI) and InfuSystem Holdings, Inc. have announced an exclusive U.S. distribution agreement with ChemoMouthpiece, , along with a minority investment. The deal involves:
1. SI Healthcare Technologies, a 50/50 joint venture between Sanara and InfuSystem, becoming the exclusive U.S. distributor of ChemoMouthpiece's kits.
2. Sanara investing $5 million for a 6.6% ownership in ChemoMouthpiece.
3. Distribution of a 510(k) cleared cryotherapy device to reduce oral mucositis in chemotherapy patients.
4. A market opportunity estimated at over $600 million, targeting 500,000 - 1,000,000 annual patients.
5. Potential for cost reductions in oncology treatment centers and improved patient quality of life.
Sanara MedTech Inc. (NASDAQ: SMTI) reported its Q2 2024 results, marking its eleventh consecutive record revenue quarter. The company achieved $20.2 million in sales, a 28% increase from Q2 2023. Despite this growth, Sanara reported a net loss of $3.5 million, compared to a $1.9 million loss in Q2 2023. The increased loss was primarily due to higher SG&A costs, executive separation expenses, and acquisition costs.
Positive developments include Adjusted EBITDA of $0.6 million, improved from -$0.3 million in Q2 2023, and expanded market presence with products sold in over 1,100 facilities across 34 states. Sanara also secured a $55 million non-dilutive term loan to support growth initiatives and made key executive appointments to strengthen its management team.
Sanara MedTech Inc. (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies for surgical, chronic wound, and skincare markets, has announced the dates for its second quarter 2024 earnings release and conference call. The company will issue its earnings release on Monday, August 12, 2024, followed by a conference call on Tuesday, August 13, 2024, at 9:00 a.m. Eastern Time.
Investors can access the conference call via a toll-free number (888-506-0062 for domestic callers, 973-528-0011 for international callers) using the access code 984768. A telephonic replay will be available until August 27, 2024. Additionally, a live webcast of the call will be accessible on the company's website under the Investor Relations section, with a one-year online replay available after the broadcast.
Sanara MedTech Inc. announced its first quarter 2024 results, showcasing a tenth consecutive record revenue quarter with $18.5 million in sales. The company appointed new executive members, entered a $55.0 million non-dilutive term loan agreement, and saw its former CEO resign. Sanara also focused on increasing product usage, resulting in a 19% revenue increase. However, the company reported a net loss of $1.8 million for the quarter, primarily due to increased SG&A costs.
Sanara MedTech Inc., a medical technology company, announced the details for the release of its first quarter earnings for the period ending March 31, 2024. The company will issue its earnings release on May 13, 2024, and host a conference call on May 14, 2024, at 9:00 a.m. Eastern Time. Investors can access the call via phone or webcast.
FAQ
What is the current stock price of Sanara MedTech (SMTI)?
What is the market cap of Sanara MedTech (SMTI)?
What is Sanara MedTech Inc. known for?
What products does Sanara MedTech offer?
Who are the primary customers for Sanara MedTech's products?
Where is Sanara MedTech Inc. headquartered?
When was Sanara MedTech Inc. founded?
How does Sanara MedTech contribute to healthcare cost reduction?
What forms does CellerateRX come in?
What conditions can CellerateRX treat?
How does Sanara MedTech ensure transparent communication with investors?
Who is the current Director of Investor Relations at Sanara MedTech?
